Patients at Hong Kong’s public hospitals and clinics may need to pay more for their prescriptions, with authorities reviewing the current heavily subsidised HK$15 (US$1.92) fee for a 16-week supply of medicine.
Without disclosing details of the fee adjustment review, Dr Simon Tang Yiu-hang, director of cluster services at the Hospital Authority, said the aim was not to cut costs but to boost resources for cancer and rare-disease patients in need of expensive, patented drugs.
